Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Revenue is far less than expected.
Not pretty overall, given the Q included sales from Graphene Labs.
Site got hacked.
Fixed now and added more security.
"noise has not been an issue with the mapping tools being used now"
Not sure I agree there, but I'm sure further studies at Mayo Clinic will point that out.
$BSGM uplisting to NASDAQ soon, 7 mil. float.
Great article by Jason Naopdano here:
http://www.bionapcfa.com/2016/04/medtech-is-outperforming-heres-name-to.html
and my interview with CEO (today) here:
http://microcapresearch.com/biosig-technologies-interview/
8-K out....
On December 17, 2014, Bio Alternative Medical Devices Ltd., ("Bio-AMD Ltd.") a majority owned subsidiary of Bio-AMD Inc., entered into a Master Agreement (the "Agreement") with Sysmex Corporation ("Sysmex") to jointly conduct a feasibility study (the "Study") for the potential development of a medical point-of-care reader device with disposable test strips for PT-INR assays and new future assays in the field of hemostasis (the "Product") based on the Bio-AMD Ltd. COAG technology.
Bio-AMD Ltd. believes it has successfully completed the Study.
On April 08, 2016 by telephone voice message, and again on a voice call on April 11, 2016, Bio-AMD Ltd. was informed telephonically by Sysmex that the Study and the Product next phase was a "number one priority for Sysmex." Accordingly, up to and including April 11, 2016, Bio-AMD Ltd. had every reason to believe the Study would proceed into a next phase.
On April 12, 2016, Bio-AMD Ltd., without warning, was informed telephonically by Sysmex that Sysmex was not planning to proceed with the Study. Bio-AMD Ltd. is awaiting written confirmation of Sysmex's decision and clarification of its reasons to curtail the Product development contemplated by the Agreement.
In light of the foregoing development with Sysmex, Bio-AMD Inc. and Bio-AMD Ltd. are considering different options for its COAG technology. Because we believe that the COAG technology has been considerably advanced during the Project and may now be considered a less risky endeavor, we believe there may be interest from other companies to pursue the COAG technology. Prior to and during the Study, Bio-AMD Ltd. received expressions of interest from more than one party for use of the COAG technology that could not be pursued due to the terms of the Agreement. Bio-AMD Ltd. will now, as a priority, explore those options and attempt to develop other options with a view to gaining another partner to commercialize its COAG technology. No assurance can be given that we will be successful in obtaining a commercialization partner or otherwise being able to obtain value from our COAG technology.
https://biz.yahoo.com/e/160414/biad8-k.html
yes, it will be an exciting IPO!
yes, looks like they're still in the running with Sysmex.
Just have to wait (we're getting good at that!) for the real deal to be announced...or not.
Still up in the air as far as I can tell.
Interesting things taking shape at Prodways.
Thanks for posting
$ABRW - American Brewing Company - new CEO is former C-Level exec. from both Coca-Cola and Anheuser-Busch (InBev)
CEO having shareholder call TOMORROW at 11:00 am EST
http://finance.yahoo.com/news/american-brewing-launches-b-cha-090000191.html
Huge marketing campaign starting and I expect big new distribution deal to be announced
$ABRW: Amazing to think that a C-level executive from Coke, and Bud/InBev, that could go anywhere he wants chose to lead American Brewing.
But then, he knows what's up in the market, and it's NOT soda sales.
see: US soda sales have been dropping for last decade and 2016 looks no better.
Vs Kombucha, which has a CAGR of 25-45% (depending on the source) and the Bucha brand has a 9 month shelf life (vs. 90 days for competitors), and doesn't have that sour taste many other kombucha drinks have (I've tried it and like it myself).
Looking forward to tomorrow's conference call!
"...the results presented to Sysmex which is now clarifying the plan for the next phase of development."
interesting....
Graphene 3D lab investor update
http://www.graphene3dlab.com/s/news.asp?ReportID=743501&_Type=News&_Title=Graphene-3D-Lab-Establishes-New-Industrial-Materials-Division-Shareholder-U...
But most significant for me is guidance for $+5 million in sales by end of 2016
(slide 10)
http://www.graphene3dlab.com/i/pdf/presentation/GGG_IP.pdf
Also- nice write-up in 3Dprint.com
http://3dprint.com/126047/graphene-3d-lab-industrial/
_____________________________________________________________________
- please note I am no longer being paid by any company or any individual for stock promo
I like Arcam, DDD, SSYS, and penny stocks GGG.V/GPHBF and SGLB
SGLB going thru reverse/uplist currently.
It would work with continued exposure to thousands of investors.
It would work with published weekly updates that go out to connections within the industry. It would work by a publisher who does not take shares for "pump and dump" purposes, but is hired as a consultant, and believes in the company and its prospects.
But not many of those around. And SGLB languishes in the land of the unknown- can't uplist without a big reverse split, and will get no traction until either uplisted, or delivers absolutely stunning results.
I know a 3D printing related stock that is projected to make $5M in sales this year and has a market cap that's half of what SGLB has. Why? Because hardly anybody knows about it.
Bottom line is it takes more than good financials- it takes exposure to the right investors....most of which are NOT on Yahoo and Ihub.
There is a thing we've all seen as P&D, and then there's investor awareness, and TRUE investor relations....where emails are actually answered by the IR rep. Difference is night and day.
Well, they've got the high quality deals/associations in place now...and only Yahoo and IHUB penny stock traders know about them.
Would anybody even know about it if SGLB were to make lets say $5M in sales this year?
The fact is, it's an EXTREMELY tough job for microcap and nanocap stocks to find investors these days- even those with good fundamentals (which SGLB still has to show).
$OASM video of technology
$OASM - Oasmia Pharmaceuticals – Advancing Nanotechnology Based Chemotherapies
Good read by Jason Napodono
http://www.bionapcfa.com/2016/03/oasmia-pharmaceuticals-advancing.html
Graphene 3D Lab’s New Scorpion Flexible Nylon Filament Takes the Sting Out of Adhesion Issues
http://3dprint.com/122852/scorpion-flexible-nylon/
SGLB's partnerships with leading aerospace and additive manufacturing companies give it far more than an "air of legitimacy".
The missing ingredient is exposure to more than penny stock "investors" than you'll find here and on the Yahoo board.
re: Personally I think that's the last thing Sigma needs - a carnival barker shill lending an air of illegitimacy to this stock.
Actually, plenty of OTC companies have IR campaigns to increase investor awareness and trading volume prior to uplisting in order to decrease the size of the reverse. ONVO did this successfully not so long ago.
re: The only way this will happen is when they get listed on the NY or American exchanges.
SGLB needs to reach a broader investor base.
Today's news was very impressive but the message isn't getting to enough of the right people.
I've spoken to a few of the company's larger investors but have not been successful in getting them to commit to an IR campaign...
Breakout year predicted for 3dprinting industry
via nypost
http://on.mktw.net/1Sf3fzT
$BSGM presentation on latest cardiac/electrophysiology technology
As a former CCU and cardiac surgical unit (CSU) manager, I can speak directly to the fact that this little company (about to uplist to NASDAQ) is on to something the big boys do not have.
A very good presentation and a top notch management team.
Video may take a minute to buffer- but is worth the wait.
http://noble.mediasite.com/mediasite/Play/a90a311afa9a4796983704ee2c4853fc1d?catalog=3a734bfc-b7b0-4496-95ea-5193c0db8116
$BSGM - Technology Dev. Agreement Inked + Nasdaq Uplisting
http://finance.yahoo.com/news/biosig-technologies-initiates-technology-development-130000447.html
Nasdaq
We expect to commence trading on a national exchange in 2016
http://finance.yahoo.com/news/biosig-technologies-inc-issues-special-130000926.html
$BSGM - uplisting to NASDAQ
I really like this company. Having worked in cardiology and being acutely familiar with electrophysiology labs and their shortcomings, this company has the answer to poor ECG signal quality during ablation, and I can see a lot of demand for their device. FDA 501k expected in Q3.
NASDAQ uplist in March/April likely. One to watch!
Investor presentation:
http://cdn.irdirect.net/IR/760/1536/BioSig%20Corporate%20Presentation%20-%20February%202016.pdf
$DDD Q4 estimate tops expectations
Q4 rev. estimated at $183M vs. consensus estimate $161M
http://finance.yahoo.com/news/3d-systems-announces-conference-call-133000646.html
Glad to hear that!
Wasn't sure anyone gave a darn anymore, lol.
But despite the very weak results from public leaders DDD and SSYS...mostly due to overpaying for non-organic growth... it seems practically everything I read and hear regarding the industry's growth is very positive. Anyone who has seen the results in the past few quarters from Arcam knows that the growth is definitely there in aerospace, health care/surgical and auto markets.
And incidentally, I'm not doing any pr/IR work for any 3D printing related companies now...so hopefully people will see me as being less biased.
Although anyone who is long or short a stock is biased at the outset when you think about it.
New investor presentation from Graphene 3D Lab shows +5$M in sales this year
That deal with the Fortune 500 company announced in December likely the source.
http://www.graphene3dlab.com/i/pdf/presentation/GGG_IP.pdf
I plan to begin writing about 3D printing stocks on my site again soon.
I prefer GGG.V as its more liquid than GPHBF.
What I'd really like is to see them list in the US on the OTC QX as their primary market since they're located in NY. Then (eventually) uplist.
With "$+5M in revenues" expected this year, I think this (uplist in the US) is possible at some point- maybe in 2017?
Not much- it's all about the coming quarters, now that the company is guiding for $5M+ in annual revenues for 2016.
...and the wait goes on.
its on their website
here's the link
http://www.graphene3dlab.com/i/pdf/presentation/GGG_IP.pdf
"...for a 30% gain from $1.50 entry yesterday"
Very nice!
Or big pharma.
I wrote (a little about that here recently)
http://microcapresearch.com/22nd-century-group-2016/
and Jason Naopdono all over it
http://seekingalpha.com/instablog/282594-jason-napodano-cfa/4632646-why-you-should-get-to-know-22nd-century-group
You might want to check out the revenue projected by management for 2016 in the updated investor presentation. They must feel pretty confident they'll be able to deliver on the milestones in their agreement with the Fortune 500 company that's working with them.
My only guess as to why they (or someone else) hasn't done so already is they're waiting for word from FDA. "Penny wise and pound foolish" given the current market cap here if you ask me, but they haven't asked me yet....
$XXII FDA moving FAST on the Modified Risk Tobacco application
http://finance.yahoo.com/news/22nd-century-meets-fda-historic-152700215.html …
Also- Jason Naopdono weighs in...
http://www.bionapcfa.com/2016/01/22nd-century-group-filed-modified-risk.html
$GGG.V - real world business/industrial applications
table for wine tasting using conductive, 3D printed wine glasses
From Graphene 3D Lab
Forbes- "8 Hot 3D Printing Trends To Watch In 2016"
2. Pushing The Limits Of Technology
While GE and Ford have touted their rapid progress with 3D printing, many others are achieving some incredible accomplishments behind closed doors. There are more than a dozen secret projects that I know of that are truly pushing the limits of 3D printing technology. Look for exciting announcements about exotic new 3D printing materials such as glass and graphene ....
http://www.forbes.com/sites/ricksmith/2016/01/12/8-hot-3d-printing-trends-to-watch-in-2016/#2715e4857a0b62be58e1319a
Happy to say I picked the best 3D printer OEM stock of 2015 a year ago
http://finance.yahoo.com/news/why-expert-thinks-theres-more-141545218.html
Still own Arcam- but sold all other 3DP-related stocks but Graphene 3D Lab.